A major study reports that the Meningitis B (MenB) vaccine does not provide protection against gonorrhoea in men who are offered it as a preventive measure. Researchers say the vaccine fails to reduce the likelihood of gonorrhoea infection in the at-risk group examined, contradicting any expectation that the MenB vaccine could confer cross-protection against the bacteria that cause gonorrhoea.
The findings are based on analysis presented by scientists, who conclude that the vaccine’s effect on meningitis B is not translating into reduced gonorrhoea risk. The reporting emphasizes that the study’s results point to a lack of benefit for men targeted by the vaccine program for gonorrhoea prevention.
Overall, the sources describe the same core conclusion: despite being administered to a population considered at higher risk, the MenB vaccine does not prevent gonorrhoea infections. The claim is presented as a significant update for public health discussions around potential vaccine-based strategies for gonorrhoea prevention.
